vs

Side-by-side financial comparison of AVITA Medical, Inc. (RCEL) and RIVERVIEW BANCORP INC (RVSB). Click either name above to swap in a different company.

AVITA Medical, Inc. is the larger business by last-quarter revenue ($17.6M vs $14.0M, roughly 1.3× RIVERVIEW BANCORP INC). RIVERVIEW BANCORP INC runs the higher net margin — 9.8% vs -66.0%, a 75.8% gap on every dollar of revenue. On growth, RIVERVIEW BANCORP INC posted the faster year-over-year revenue change (10.4% vs -4.3%). RIVERVIEW BANCORP INC produced more free cash flow last quarter ($-736.0K vs $-6.1M). Over the past eight quarters, AVITA Medical, Inc.'s revenue compounded faster (26.0% CAGR vs 24.6%).

Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East...

Riverview Bancorp Inc. is a U.S.-based bank holding company operating Riverview Community Bank, primarily serving the Pacific Northwest region. It offers personal and commercial banking products including savings accounts, consumer loans, mortgages, commercial lending, and small business financial solutions for retail customers and local enterprises.

RCEL vs RVSB — Head-to-Head

Bigger by revenue
RCEL
RCEL
1.3× larger
RCEL
$17.6M
$14.0M
RVSB
Growing faster (revenue YoY)
RVSB
RVSB
+14.7% gap
RVSB
10.4%
-4.3%
RCEL
Higher net margin
RVSB
RVSB
75.8% more per $
RVSB
9.8%
-66.0%
RCEL
More free cash flow
RVSB
RVSB
$5.4M more FCF
RVSB
$-736.0K
$-6.1M
RCEL
Faster 2-yr revenue CAGR
RCEL
RCEL
Annualised
RCEL
26.0%
24.6%
RVSB

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
RCEL
RCEL
RVSB
RVSB
Revenue
$17.6M
$14.0M
Net Profit
$-11.6M
$1.4M
Gross Margin
81.2%
Operating Margin
-59.1%
12.4%
Net Margin
-66.0%
9.8%
Revenue YoY
-4.3%
10.4%
Net Profit YoY
-0.3%
11.8%
EPS (diluted)
$-0.37
$0.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RCEL
RCEL
RVSB
RVSB
Q4 25
$17.6M
$14.0M
Q3 25
$17.1M
$13.6M
Q2 25
$18.4M
$13.3M
Q1 25
$18.5M
$12.9M
Q4 24
$18.4M
$12.7M
Q3 24
$19.5M
$12.8M
Q2 24
$15.2M
$12.2M
Q1 24
$11.1M
$9.0M
Net Profit
RCEL
RCEL
RVSB
RVSB
Q4 25
$-11.6M
$1.4M
Q3 25
$-13.2M
$1.1M
Q2 25
$-9.9M
$1.2M
Q1 25
$-13.9M
$1.1M
Q4 24
$-11.6M
$1.2M
Q3 24
$-16.2M
$1.6M
Q2 24
$-15.4M
$966.0K
Q1 24
$-18.7M
$-3.0M
Gross Margin
RCEL
RCEL
RVSB
RVSB
Q4 25
81.2%
Q3 25
81.3%
Q2 25
81.2%
Q1 25
84.7%
Q4 24
87.6%
Q3 24
83.7%
Q2 24
86.1%
Q1 24
86.4%
Operating Margin
RCEL
RCEL
RVSB
RVSB
Q4 25
-59.1%
12.4%
Q3 25
-53.6%
10.2%
Q2 25
-60.5%
11.7%
Q1 25
-63.9%
11.3%
Q4 24
-54.1%
12.4%
Q3 24
-70.6%
15.5%
Q2 24
-102.8%
10.0%
Q1 24
-155.0%
-47.5%
Net Margin
RCEL
RCEL
RVSB
RVSB
Q4 25
-66.0%
9.8%
Q3 25
-77.3%
8.1%
Q2 25
-53.9%
9.2%
Q1 25
-74.9%
8.9%
Q4 24
-63.0%
9.7%
Q3 24
-82.9%
12.2%
Q2 24
-101.3%
7.9%
Q1 24
-168.0%
-34.7%
EPS (diluted)
RCEL
RCEL
RVSB
RVSB
Q4 25
$-0.37
$0.07
Q3 25
$-0.46
$0.05
Q2 25
$-0.38
$0.06
Q1 25
$-0.53
$0.05
Q4 24
$-0.44
$0.06
Q3 24
$-0.62
$0.07
Q2 24
$-0.60
$0.05
Q1 24
$-0.73
$-0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RCEL
RCEL
RVSB
RVSB
Cash + ST InvestmentsLiquidity on hand
$18.2M
$28.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$-16.6M
$164.2M
Total Assets
$56.4M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RCEL
RCEL
RVSB
RVSB
Q4 25
$18.2M
$28.6M
Q3 25
$23.3M
$32.8M
Q2 25
$15.7M
$34.2M
Q1 25
$25.8M
$29.4M
Q4 24
$35.9M
$25.3M
Q3 24
$44.4M
$31.0M
Q2 24
$54.1M
$27.8M
Q1 24
$68.2M
$23.6M
Stockholders' Equity
RCEL
RCEL
RVSB
RVSB
Q4 25
$-16.6M
$164.2M
Q3 25
$-6.7M
$163.5M
Q2 25
$-12.9M
$162.0M
Q1 25
$-4.6M
$160.0M
Q4 24
$4.5M
$158.3M
Q3 24
$12.2M
$160.8M
Q2 24
$23.9M
$155.9M
Q1 24
$32.6M
$155.6M
Total Assets
RCEL
RCEL
RVSB
RVSB
Q4 25
$56.4M
$1.5B
Q3 25
$63.7M
$1.5B
Q2 25
$58.1M
$1.5B
Q1 25
$69.6M
$1.5B
Q4 24
$79.7M
$1.5B
Q3 24
$81.1M
$1.5B
Q2 24
$87.8M
$1.5B
Q1 24
$97.4M
$1.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RCEL
RCEL
RVSB
RVSB
Operating Cash FlowLast quarter
$-5.4M
$-506.0K
Free Cash FlowOCF − Capex
$-6.1M
$-736.0K
FCF MarginFCF / Revenue
-34.7%
-5.2%
Capex IntensityCapex / Revenue
3.8%
1.6%
Cash ConversionOCF / Net Profit
-0.37×
TTM Free Cash FlowTrailing 4 quarters
$-33.5M
$20.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RCEL
RCEL
RVSB
RVSB
Q4 25
$-5.4M
$-506.0K
Q3 25
$-5.2M
$16.8M
Q2 25
$-10.2M
$-697.0K
Q1 25
$-10.3M
$8.3M
Q4 24
$-8.1M
$2.2M
Q3 24
$-7.2M
$764.0K
Q2 24
$-12.8M
$5.4M
Q1 24
$-20.9M
$12.8M
Free Cash Flow
RCEL
RCEL
RVSB
RVSB
Q4 25
$-6.1M
$-736.0K
Q3 25
$-6.2M
$16.4M
Q2 25
$-10.8M
$-773.0K
Q1 25
$-10.5M
$5.6M
Q4 24
$-9.7M
$1.9M
Q3 24
$-11.0M
$-1.4M
Q2 24
$-15.4M
$5.3M
Q1 24
$-22.0M
$7.1M
FCF Margin
RCEL
RCEL
RVSB
RVSB
Q4 25
-34.7%
-5.2%
Q3 25
-36.1%
120.1%
Q2 25
-58.4%
-5.8%
Q1 25
-56.9%
43.1%
Q4 24
-52.7%
15.0%
Q3 24
-56.1%
-11.3%
Q2 24
-101.6%
43.7%
Q1 24
-198.2%
79.0%
Capex Intensity
RCEL
RCEL
RVSB
RVSB
Q4 25
3.8%
1.6%
Q3 25
5.5%
2.9%
Q2 25
2.8%
0.6%
Q1 25
1.2%
21.0%
Q4 24
8.8%
2.4%
Q3 24
19.2%
17.3%
Q2 24
17.5%
0.9%
Q1 24
10.3%
62.0%
Cash Conversion
RCEL
RCEL
RVSB
RVSB
Q4 25
-0.37×
Q3 25
15.25×
Q2 25
-0.57×
Q1 25
7.20×
Q4 24
1.79×
Q3 24
0.49×
Q2 24
5.63×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons